IV oncology treatments are associated with severe side effects (SEs) that can decrease patients’ quality of life and lead to increased hospitalizations. However, improved reporting with remote monitoring systems (RMSs) may decrease patients’ treatment-related SE burden and improve quality of life. For this project, participants wore the BioIntelliSense BioSticker™, a medical-grade remote monitoring device. Data on participants’ heart rates, respiratory rates, and temperatures were collected and transmitted, which alerted clinicians to follow up with participants for SE management if clinical data were outside of target ranges. All project variables except for hospitalizations showed a statistically significant decrease from pre- to post-test. Of the 13 SEs evaluated, 3 showed a statistically significant decrease in severity from pre- to post-test.